Advertisement

Heart and Vessels

, Volume 33, Issue 2, pp 102–112 | Cite as

Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry

  • Michiyo Shiiba
  • Bo Zhang
  • Shin-ichiro MiuraEmail author
  • Amane Ike
  • Daisuke Nose
  • Takashi Kuwano
  • Satoshi Imaizumi
  • Makoto Sugihara
  • Atushi Iwata
  • Hiroaki Nishikawa
  • Akira Kawamura
  • Kazuyuki Shirai
  • Shin’ichiro Yasunaga
  • Keijiro SakuEmail author
Original Article
  • 161 Downloads

Abstract

It is not yet clear whether the discordance of low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) predicts the follow-up clinical outcome (major adverse cardiovascular events: MACEs) in patients with coronary stent implantation. Among 2015 patients with coronary stent implantation (Fukuoka University [FU]-Registry), excluding those with acute coronary syndrome or hemodialysis, we selected 801 patients who had undergone successful stent implantation with a follow-up until 18 months, and classified them into 3 groups according to baseline LDL-C and non-HDL-C levels [percentile(P)non-HDL-C more than (P)LDL-C, (P)non-HDL-C equal to (P)LDL-C, and (P)non-HDL-C less than (P) LDL-C]. We found that the discordance of (P)LDL-C and (P)non-HDL-C was not a significant predictor of MACEs. Higher LDL-C level was consistently and independently associated with higher incidences of MACEs after controlling for conventional risk factors and the type of stent used by multivariate Cox regression analyses. In conclusion, LDL-C levels are more important than non-HDL-C levels and the discordance of LDL-C and non-HDL-C levels as predictors of MACEs in patients with stable angina after stent implantation.

Keywords

Low-density lipoprotein cholesterol Non-high-density lipoprotein cholesterol Major adverse cardiovascular events Coronary stent implantation 

Notes

Compliance with ethical standards

Disclosures

Research and education grants, and payments for consulting and promotional speaking (KeS) were received from MSD Co., SANOFI, Takeda Pharmaceutical Co., Ltd., Bayer, Eli Lilly, Co. (clinical research grant), and TOA EIYO Co. KeS and MS are Directors of NPO Clinical and Applied Science, Fukuoka, Japan. KaS, SM, and KeS had received a grant from the Public Interest Incorporated Foundation of “Clinical Research Promotion Foundation” in Fukuoka, Japan, and part of this work was transferred to NPO Clinical and Applied Science, Fukuoka, Japan. KeS has an Endowed Department of Molecular Cardiovascular Therapeutics (YU, SM), Fukuoka University, supported by MSD Co., Ltd, and an Endowed Department of Community and Emergency Medicine (HN, MS), Fukuoka University, supported by Izumi City, Kagoshima, Japan.

Supplementary material

380_2017_1036_MOESM1_ESM.doc (876 kb)
Supplementary material 1 (DOC 875 kb)
380_2017_1036_MOESM2_ESM.doc (312 kb)
Supplementary material 2 (DOC 312 kb)

References

  1. 1.
    Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368:1155–1163CrossRefPubMedGoogle Scholar
  2. 2.
    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, Group JS (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207CrossRefPubMedGoogle Scholar
  3. 3.
    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets I (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435CrossRefPubMedGoogle Scholar
  4. 4.
    Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, and Incremental Decrease in End Points Through Aggressive Lipid Lowering Study G (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437–2445CrossRefGoogle Scholar
  5. 5.
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin E, and Infection Therapy-Thrombolysis in Myocardial Infarction I (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504CrossRefPubMedGoogle Scholar
  6. 6.
    Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM, Group TNTS, Group IS (2008) Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117:3002–3009CrossRefPubMedGoogle Scholar
  7. 7.
    National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A (2002) Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421Google Scholar
  8. 8.
    Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, European Society of C, and European Atherosclerosis S (2011) ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217:3CrossRefPubMedGoogle Scholar
  9. 9.
    Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017Google Scholar
  10. 10.
    Sniderman AD, Lamarche B, Contois JH, de Graaf J (2014) Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB. Curr Opin Lipidol 25:461–467CrossRefPubMedGoogle Scholar
  11. 11.
    Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD (2011) A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 4:337–345CrossRefPubMedGoogle Scholar
  12. 12.
    Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL (2001) Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 161:1413–1419CrossRefPubMedGoogle Scholar
  13. 13.
    Sniderman AD, Islam S, Yusuf S, McQueen MJ (2013) Is the superiority of apoB over non-HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables? J Clin Lipidol 7:626–631CrossRefPubMedGoogle Scholar
  14. 14.
    Mora S, Buring JE, Ridker PM (2014) Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation 129:553–561CrossRefPubMedGoogle Scholar
  15. 15.
    Ike A, Shirai K, Nishikawa H, Iwata A, Yahiro E, Sugihara M, Kawamura A, Uehara Y, Zhang B, Ogawa M, Mori K, Miura S, Saku K (2015) Associations between different types of hypoglycemic agents and the clinical outcome of percutaneous coronary intervention in diabetic patients-from the FU-Registry. J Cardiol 65:390–396CrossRefPubMedGoogle Scholar
  16. 16.
    Ike A, Nishikawa H, Shirai K, Mori K, Kuwano T, Fukuda Y, Takamiya Y, Yanagi D, Kubota K, Tsuchiya Y, Zhang B, Miura S, Saku K (2011) Impact of glycemic control on the clinical outcome in diabetic patients with percutaneous coronary intervention—from the FU-registry. Circ J 75:791–799CrossRefPubMedGoogle Scholar
  17. 17.
    Nagata I, Ike A, Nishikawa H, Zhang B, Sugihara M, Mori K, Iwata A, Kawamura A, Shirai K, Uehara Y, Ogawa M, Miura S, Saku K (2015) Associations between lipid profiles and MACE in hemodialysis patients with percutaneous coronary intervention: from the FU-Registry. J Cardiol 65:105–111CrossRefPubMedGoogle Scholar
  18. 18.
    Japanese Circulation Society (2011) Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011) http://www.j-circ.or.jp/guideline/pdf/JCS2011_ogawah_h.pdf. Accessed 5 Jan 2013
  19. 19.
    Sniderman AD, Islam S, Yusuf S, McQueen MJ (2012) Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis 225:444–449CrossRefPubMedGoogle Scholar
  20. 20.
    Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr (2011) Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 5:105–113CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Westfall PH, Tobias RD, Wolfinger RD (2011) Multiple Comparisons and Multiple Tests Using SAS, 2nd edn. SAS Institute Inc., Cary, pp 273–289Google Scholar
  22. 22.
    Allison PD (2010) Survival analysis using SAS. A practical guide, 2nd edn. SAS Institute Inc., Cary, pp 204–233Google Scholar
  23. 23.
    Matange S, Heath D (2011) Statistical graphics procedures by example: effective graphs using SAS, 2nd edn. SAS Institute Inc., Cary, pp 61–88Google Scholar
  24. 24.
    Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, American College of Cardiology/American Heart Association Task Force on Practice G (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:2889–2934CrossRefPubMedGoogle Scholar
  25. 25.
    Sniderman A, McQueen M, Contois J, Williams K, Furberg CD (2010) Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol 4:152–155CrossRefPubMedGoogle Scholar
  26. 26.
    Lawler PR, Akinkuolie AO, Ridker PM, Sniderman AD, Buring JE, Glynn RJ, Chasman DI, Mora S (2017) Discordance between circulating atherogenic cholesterol mass and lipoprotein particle concentration in relation to future coronary events in women. Clin Chem 63:870–879CrossRefPubMedGoogle Scholar
  27. 27.
    Saku K, Zhang B, Noda K, Investigators PT (2011) Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J 75:1493–1505CrossRefPubMedGoogle Scholar
  28. 28.
    Zhang B, Matsunaga A, Rainwater DL, Miura S, Noda K, Nishikawa H, Uehara Y, Shirai K, Ogawa M, Saku K (2009) Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study. J Lipid Res 50:1832–1841CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Zhang B, Miura S, Yanagi D, Noda K, Nishikawa H, Matsunaga A, Shirai K, Iwata A, Yoshinaga K, Adachi H, Imaizumi T, Saku K (2008) Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: the SPECIAL Study. Atherosclerosis 201:353–359CrossRefPubMedGoogle Scholar
  30. 30.
    Zhang B, Katafuchi R, Arishima H, Matsunaga A, Rye KA, Saku K (2006) Effects of atorvastatin and apoA-I/phosphatidylcholine discs on triglyceride-rich lipoprotein subfractions as characterized by capillary isotachophoresis. Clin Chim Acta 373:55–61CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan KK 2017

Authors and Affiliations

  • Michiyo Shiiba
    • 1
    • 2
  • Bo Zhang
    • 3
  • Shin-ichiro Miura
    • 2
    • 4
    Email author
  • Amane Ike
    • 2
  • Daisuke Nose
    • 2
    • 5
  • Takashi Kuwano
    • 2
  • Satoshi Imaizumi
    • 2
  • Makoto Sugihara
    • 2
  • Atushi Iwata
    • 2
  • Hiroaki Nishikawa
    • 2
  • Akira Kawamura
    • 2
  • Kazuyuki Shirai
    • 5
    • 6
  • Shin’ichiro Yasunaga
    • 3
  • Keijiro Saku
    • 2
    • 4
    Email author
  1. 1.Fukuoka Jo Gakuin UniversityFukuokaJapan
  2. 2.Department of CardiologyFukuoka University School of MedicineFukuokaJapan
  3. 3.Department of BiochemistryFukuoka University School of MedicineFukuokaJapan
  4. 4.Department of Molecular Cardiovascular TherapeuticsFukuoka University School of MedicineFukuokaJapan
  5. 5.Division of CardiologyHakujyuji HospitalFukuokaJapan
  6. 6.Department of Cardiovascular MedicineFukuoka University Chikushi HospitalFukuokaJapan

Personalised recommendations